Eli Lilly: diabetes drug reduces heart risks in trial
(CercleFinance.com) - Eli Lilly's Trulicity diabetes drug significantly reduced major adverse cardiovascular events in a placebo-controlled trial, meeting the study's primary efficacy objective, the US drugmaker said on Monday.
Eli Lilly's once-weekly drug is the first type 2 diabetes medicine to demonstrate superiority in the reduction of cardiovascular death, heart attack or non-fatal stroke, in a clinical trial that includes a majority of participants who did not have established cardiovascular disease, the company said.
The study compared the effect of once-weekly Trulicity 1.5 mg to placebo when added to standard of care.
"These data further validate Trulicity as a well-established option for people with type 2 diabetes," the group said.
People with type 2 diabetes face a higher risk of cardiovascular disease.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Eli Lilly's once-weekly drug is the first type 2 diabetes medicine to demonstrate superiority in the reduction of cardiovascular death, heart attack or non-fatal stroke, in a clinical trial that includes a majority of participants who did not have established cardiovascular disease, the company said.
The study compared the effect of once-weekly Trulicity 1.5 mg to placebo when added to standard of care.
"These data further validate Trulicity as a well-established option for people with type 2 diabetes," the group said.
People with type 2 diabetes face a higher risk of cardiovascular disease.
Copyright (c) 2018 CercleFinance.com. All rights reserved.